Sep 17, 2020
SANTA MONICA, CA / ACCESSWIRE / September 17, 2020 / BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced the pricing of an underwritten public offering of 1,565,200 shares of Class A common stock at a pu...
Jun 16, 2020
Hariri, Gorlin, and Rogich to Contribute Their Tremendous Industry Insights and Stature
Jun 11, 2020
Novel BIV201 Formulation Shows Significant Improvements Over Industry TerlipressinPrefilled Syringe May Significantly Extend Market Protection Beyond Orphan Drug Exclusivity